Hydrochloric Acid → N-(1-(1-((2-Chloro-6-methylpyridin-4-yl)methyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide

HRID 2099827ノート

反応式

HRID 2099827 の反応式
[Cl:1][C:2]1[CH:7]=[C:6]([CH2:8][N:9]2[CH:13]=[CH:12][N:11]=[C:10]2[CH:14]([NH:34][C:35](=O)[O:36]C(C)(C)C)[CH2:15][C:16]2[CH:24]=[C:23]([CH3:25])[C:22]3[C:18](=[CH:19][N:20](COCC[Si](C)(C)C)[N:21]=3)[CH:17]=2)[CH:5]=[C:4]([CH3:42])[N:3]=1.Cl.C(C1NC=CN=1)(C1NC=CN=1)=O.[NH:56]1[CH2:61][CH2:60][CH:59]([N:62]2[CH2:71][C:70]3[C:65](=[CH:66][CH:67]=[CH:68][CH:69]=3)[NH:64][C:63]2=[O:72])[CH2:58][CH2:57]1>C(OCC)(=O)C>[Cl:1][C:2]1[CH:7]=[C:6]([CH2:8][N:9]2[CH:13]=[CH:12][N:11]=[C:10]2[CH:14]([NH:34][C:35]([N:56]2[CH2:57][CH2:58][CH:59]([N:62]3[CH2:71][C:70]4[C:65](=[CH:66][CH:67]=[CH:68][CH:69]=4)[NH:64][C:63]3=[O:72])[CH2:60][CH2:61]2)=[O:36])[CH2:15][C:16]2[CH:17]=[C:18]3[C:22](=[C:23]([CH3:25])[CH:24]=2)[NH:21][N:20]=[CH:19]3)[CH:5]=[C:4]([CH3:42])[N:3]=1

参加物

6

反応物 4

HCID 313Hydrochloric AcidHCID 5250894Bis-(1H-imidazol-2-YL)-methanoneHCID 110425973-(Piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-oneHCID 57794619tert-Butyl 1-(1-((2-chloro-6-methylpyridin-4-yl)methyl)-1H-imidazol-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate

生成物 1

HCID 11422298N-(1-(1-((2-Chloro-6-methylpyridin-4-yl)methyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide

試薬・触媒・溶媒 1

HCID 8857Ethyl Acetate溶媒

反応条件

温度
0 °C

実験手順

tert-Butyl 1-(1-((2-chloro-6-methylpyridin-4-yl)methyl)-1H-imidazol-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate (100 mg, 0.16 mmol) was dissolved in a minimum amount of ethyl acetate, and treated with hydrochloric acid (4 N in dioxane, 2.0 mL). The mixture was stirred under nitrogen overnight. After removal of the solvents, the crude mixture was treated with diethyl ether to give a precipitate which was filtered. The resulting solid was dissolved in dimethylformamide (1.0 mL), cooled to 0° C., and treated with carbonyl diimidazole (27.0 mg, 0.165 mmol, 1.05 equiv) and N′N-diisopropylethylamine (66.0 μL, 3.0 equiv). The reaction was stirred for 5 min at 0° C., warmed to room temperature, stirred for 10 min, and treated with 3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (44.0 mg, 0.165 mmol, 1.05 equiv). The mixture was stirred at room temperature overnight. The solvent was evaporated and the residue purified by column chromatography to afford 67.1 mg (65%, 2 steps). 1H-NMR (CD3OD, 500 MHz) δ 1.43-1.62 (m, 4H), 2.27 (s, 3H), 2.46 (s, 3H), 2.65-2.77 (m, 3H), 3.22-3.30 (m, 1H), 3.95-4.07 (m, 2H), 4.19 (s, 2H), 4.30-4.38 (m, 1H), 5.14-5.37 (m, 3H), 6.61 (s, 1H), 6.70 (s, 1H), 6.80 (d, J=7.9, 1H), 6.88 (s, 1H), 6.96 (dd, J=7.6, 7.3, 1H), 7.10 (s, 1H), 7.13 (s, 1H), 7.14-7.20 (m, 2H), 7.28 (s, 1H). Mass spec.: 638.1 (MH)+.

後処理

  1. customAfter removal of the solvents
  2. additionthe crude mixture was treated with diethyl ether
  3. customto give a precipitate which
  4. filtrationwas filtered
  5. dissolutionThe resulting solid was dissolved in dimethylformamide (1.0 mL)
  6. stirringThe reaction was stirred for 5 min at 0° C.
  7. temperaturewarmed to room temperature
  8. stirringstirred for 10 min
  9. stirringThe mixture was stirred at room temperature overnight
  10. customThe solvent was evaporated
  11. customthe residue purified by column chromatography
  12. customto afford 67.1 mg (65%, 2 steps)

出典と根拠

ORDレコード
ord-08c2ee56d1c644ecb58b6a233b97b524
出典データセット
uspto-grants-2009_08
特許番号
US07569578B2

反応ノート

読み込み中…